Identification of an Abbreviated Test Battery for Detection of HIV-Associated Neurocognitive Impairment in an Early-Managed HIV-Infected Cohort
|
|
- Amber Patrick
- 5 years ago
- Views:
Transcription
1 Identification of an Abbreviated Test Battery for Detection of HIV-Associated Neurocognitive Impairment in an Early-Managed HIV-Infected Cohort David J. Moore 1 *, Mollie J. P. Roediger 2,3, Lynn E. Eberly 2,3, Kaitlin Blackstone 1, Braden Hale 3,4,5, Amy Weintrob 3,6, Anuradha Ganesan 3,7, Brian K. Agan 3, Scott L. Letendre 1, Nancy F. Crum-Cianflone 3,4,5 1 HIV Neurobehavioral Research Program, San Diego, California, United States of America, 2 Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, United States of America, 3 Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America, 4 HIV Clinic, Naval Medical Center San Diego, San Diego, California, United States of America, 5 Naval Health Research Center, San Diego, California, United States of America, 6 Walter Reed National Military Medical Center, Bethesda, Maryland, United States of America, 7 Infectious Disease Clinic, National Naval Medical Center, Bethesda, Maryland, United States of America Abstract Background: HIV-associated neurocognitive disorders (HAND) remain prevalent despite improved antiretroviral treatment (ART), and it is essential to have a sensitive and specific HAND screening tool. Methods: Participants were 200 HIV-infected US military beneficiaries, managed early in the course of HIV infection, had few comorbidities, and had open access to ART. Participants completed a comprehensive, seven-domain (16-test), neuropsychological battery (,120 min); neurocognitive impairment (NCI) was determined using a standardized score derived from demographically adjusted T-scores (global deficit score $0.5). Restricting the estimated administration time of the screening battery to, = 20 minutes, we examined the sensitivity and specificity of detecting NCI for all possible combinations of 2-, 3-, and 4- tests from the comprehensive battery. Results: Participants were relatively healthy (median CD4 count: 546 cells/mm 3 ) with 64% receiving ART. Prevalence of NCI was low (19%). The best 2-test screener included the Stroop Color Test and the Hopkins Verbal Learning Test-Revised (11 min; sensitivity = 73%; specificity = 83%); the best 3-test screener included the above measures plus the Paced Auditory Serial Addition Test (PASAT; 16 min; sensitivity = 86%; specificity = 75%). The addition of Action Fluency to the above three tests improved specificity (18 min; sensitivity = 86%; specificity = 87%). Conclusions: Combinations of widely accepted neuropsychological tests with brief implementation time demonstrated good sensitivity and specificity compared to a time intensive neuropsychological test battery. Tests of verbal learning, attention/working memory, and processing speed are particularly useful in detecting NCI. Utilizing validated, easy to administer, traditional neuropsychological tests with established normative data may represent an excellent approach to screening for NCI in HIV. Citation: Moore DJ, Roediger MJP, Eberly LE, Blackstone K, Hale B, et al. (2012) Identification of an Abbreviated Test Battery for Detection of HIV-Associated Neurocognitive Impairment in an Early-Managed HIV-Infected Cohort. PLoS ONE 7(11): e doi: /journal.pone Editor: Alan Landay, Rush University, United States of America Received May 14, 2012; Accepted September 11, 2012; Published November 8, 2012 This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Funding: Support for this work (IDCRP-016) was provided by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI Support was also obtained from the National Institute of Mental Health (UCSD HIV Neurobehavioral Research Center, P30 MH62512). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * djmoore@ucsd.edu Introduction HIV-associated neurocognitive disorders (HAND) remain prevalent despite improved antiretroviral treatment; up to 50% of HIV infected (HIV+) individuals are estimated to experience some level of neurocognitive impairment (NCI) [1]. The neurocognitive profile of HIV+ individuals is typically characterized by mild and spotty impairments; in fact, the most common form of HAND is asymptomatic neurocognitive impairment (ANI, estimated at 33% of the HIV+ population) [1], in which individuals experience impairment that does not reportedly interfere with their daily functioning. Original recommendations for the neurocognitive assessment of individuals with HIV from the National Institute of Mental Health (NIMH)-sponsored AIDS Workshop: Neuropsychological Assessment Approaches included an extensive (7 9 hr) and brief (1 2 hr) neuropsychological battery [2]. However, there is a growing demand for even briefer neurocognitive assessments, such as neurocognitive screening instruments, which can aid in the preliminary identification of individuals who may be appropriate to undergo further testing. PLOS ONE 1 November 2012 Volume 7 Issue 11 e47310
2 These screening batteries or instruments would ensure an efficient use of time and resources in both clinical and research protocols [3]. However, parsimonious selection of assessment tools that are the most sensitive and specific to the mild NCI observed in HIV+ individuals has proven challenging. Common traditional cognitive screening measures such as the Mini Mental Status Exam (MMSE) [3] and the Mattis Dementia Rating Scale (DRS) [4] were largely developed for dementing disorders and therefore primarily target cognitive functions (e.g., naming errors, gross visuospatial deficits) that are impaired as a result of posterior neocortical pathology. HIV-associated NCI, however, is typically milder in degree of impairment and more often involves pathophysiology within the fronto-striatal regions (e.g., processing speed) [5 7] than cortical dementias such as Alzheimer disease. As such, traditional cognitive screening measures are not typically sensitive enough for detecting HIVrelated NCI [8,9]. Due to the lack of sensitivity of traditional cognitive screeners, there have been attempts to develop screening instruments specific to persons with HIV disease. The HIV Dementia Scale (HDS) was developed to address these issues and has received widespread attention. Although the HDS has been shown to be more sensitive to the most severe form of HIV-related neurocognitive dysfunction (i.e., HIV-associated Dementia (HAD) [8]) than the traditional screeners (i.e., MMSE), it has not been able to reliably detect the more common form of mild HIV-related NCI [10 12]. For example, Morgan et al. [13] reported that even after demographically adjusting the scores on the HDS, the measure was still only 50% sensitive in detecting incidents of asymptomatic neurocognitive impairment. Other neurocognitive screeners that have been examined in the context of HIV infection have also failed to show sufficient sensitivity to the mild NCI observed in the early stages of infection. For example, the Mental Alteration Test showed sensitivity to HIV-associated impairment comparable to the MMSE [14]; however, since prior studies suggest that the MMSE lacks sensitivity to mild HIV impairment [8,9], it is unclear how useful the Mental Alteration Test is at detecting such deficits. Additionally, the Executive Interview (EXIT) was shown to be less sensitive to HIV-associated impairment than the HDS [15]. Lastly, Cogstate is a computerized neurocognitive screener which showed good sensitivity and specificity in individuals with advanced HIV disease (mean CD4 = 339, nadir CD4 = 76) and AIDS-defining complex (mean CD4 = 406, nadir CD4 = 137) [16], but has not been examined in less severely impaired HIV infected individuals. The International HDS (IHDS) was also developed to detect HIVrelated dementia across global populations; however, for the purposes of the current study, this measure suffers from similar shortcomings as the original HDS in that it is designed to detect dementia, rather than the more mild forms of cognitive difficulties in HIV. Currently, the IHDS has been shown to be approximately 80% sensitive and 50% specific in detecting dementia among HIV+ U.S. and Ugandan individuals [17]. Therefore, the IHDS has limitations for detecting the more common mild cognitive difficulties experienced by individuals with HIV. Also of importance when developing a novel neurocognitive screener is the consideration of the psychometric properties and ease of interpretation and clinical integration of a measure. When any novel measure is created, it is essential to establish that the validity and reliability of the measure are within the accepted range, a step that can be time-consuming and is often overlooked (e.g., reliability is not reported on the HDS). Instead, utilization of established neuropsychological measures as a cognitive screener may overcome some of these difficulties since these instruments have established psychometric properties and are widely utilized and recognized in the field of neuropsychology, which not only bolsters the validity and reliability of the screener, but also facilitates common interpretation of its results. For instance, Carey et al. [10] developed a screening battery to detect HIV-related NCI utilizing a two-measure combination of a priori selected traditional neuropsychological tests; this approach increases interpretability and familiarity of the screener to the clinician or researcher. Although the authors found good sensitivity (75 78%) by using an a priori selection of screening tests, it is not clear if the optimal measures, number of measures (e.g., the authors only included single and two test combinations), or the combination of measures was examined. Therefore, in our study we aimed to identify the best combinations of traditional neuropsychological measures to be used as a screener, that show high sensitivity and specificity to a larger comprehensive neuropsychological battery by exploring all possible combinations of two, three, and four measures. By applying this approach to a cohort of early-managed HIV-infected patients, the best screener will reflect those measures that are most sensitive and specific to mild HIV-related NCI in a cohort with relatively low levels of overall impairment. Therefore, our goal is to present a menu of the most optimal measure combinations, where the definition of optimal may be informed by sensitivity and specificity, time constraints, and/or feasibility (e.g., availability of measure materials, training). Methods Participants were 200 HIV-infected US military beneficiaries, who were diagnosed early in the course of HIV infection, had few comorbidities, and had open access to antiretroviral medications. All participants were military beneficiaries with enrollment characteristics as previously described [18]. All study participants provided written informed consent and the study was approved by a central military institutional review board. The trial was registered at ClinicalTrials.gov (Registration #NCT ). Participants completed a comprehensive, seven-domain (16- tests; 18 variables examined), neuropsychological battery (120 min) (Table 1). These tests cover a broad range of neuropsychological abilities and the battery is based on the one utilized by the large multi-site CHARTER study [1]. Raw neuropsychological (NP) test scores were converted into T-scores using demographically adjusted norms to control for the effects of age, education, gender, and where available ethnicity [19 21]. The demographically corrected T-scores were then converted into global (GDS) and domain deficit (DDS) scores according to a standardized approach [10,22]. A GDS score greater than or equal to 0.5 was used to define global NP impairment. Our goal was to establish a screening battery that was brief to administer and was both sensitive and specific to NCI as determined by global NP impairment, described above. All possible combinations of 2-, 3-, and 4- NP tests from the comprehensive battery, limited to those combinations that took no more than 20 minutes to administer, were considered (The time limitation necessarily excluded the Hopkins Verbal Learning Test-Revised and the Brief Visuospatial Memory Test-Revised Delayed Recall measures from any possible combination). To maximize domain breadth assessed by the combinations all possible combinations, regardless of domain, were considered; the approach yielded the following potential screening battery combinations: test, test, and test combinations. For each 2-test combination, screening NCI was defined as either two tests with T-score,40 or one test with T-score,35. For PLOS ONE 2 November 2012 Volume 7 Issue 11 e47310
3 Table 1. Component tests from neuropsychological battery, abbreviations, estimated administration time, and mean (SD) T-score performance for each of the measures in our sample of 200 HIV-infected individuals. Test Abbreviation Admin Time (min) T-score Mean (SD) Materials Approximate Cost Public domain vs. Copyrighted Verbal Fluency Letter Fluency FAS (9.66) Paper score sheet, Animal Fluency ANIMF (9.54) Paper score sheet, Action Fluency ACTF (10.32) Paper score sheet, Abstraction/Executive Functioning Wisconsin Card Sorting Test (WCST) (Total Errors) WCST (11.50) Computer program OR stimulus cards+ paper score sheet Trail Making Test - B TMTB (10.51) Paper stimuli, pencil, Stroop Incongruent Test STRPINC (10.87) Paper stimuli, $ (computer version) OR $ (paper version) Copyrighted $40.00 $ (Stroop kit) Copyrighted Speed of Information Processing WAIS-III Symbol Search SYMS (9.47) Paper stimuli, score $ (WAIS-III kit) Copyrighted sheet, pencil, WAIS-III Digit Symbol DSYM (9.77) Paper stimuli, score $ (WAIS-III kit) Copyrighted sheet, pencil, Trail Making Test - A TMTA (9.65) Paper stimuli, pencil, Stroop Color Test STRPCOL (11.53) Paper stimuli, $40.00 $ (Stroop Copyrighted kit) Attention/Working Memory Paced Auditory Serial Addition Test - 50 PASAT (10.06) Audio recording, paper score sheet WAIS-III Digit Span DSPAN (9.65) Paper score sheet $ (WAIS-III kit) Copyrighted Learning Brief Visuospatial Memory Test - Revised (Learning Trials) Hopkins Verbal Learning Test Revised (Learning Trials) Recall Brief Visuospatial Memory Test - Revised (Total Recall) Hopkins Verbal Learning Test Revised (Total Recall) Motor Speed and Dexterity Grooved Pegboard - dominant hand Grooved Pegboard - non-dominant hand doi: /journal.pone t001 BVMTR-LRN (8.98) Stimulus book, blank paper, pencil $ (BVMT-R kit) Copyrighted HVLTR-LRN (9.50) Paper score sheet $ (HVLT-R kit) Copyrighted BVMTR-RCL (11.11) Blank paper, pencil $ (BVMT-R kit) Copyrighted HVLTR-RCL (9.57) Paper score sheet $ (HVLT-R kit) Copyrighted PD (9.20) Pegboard, pegs, PND (9.52) Pegboard, pegs, $73 $218 Copyrighted $73 $218 Copyrighted each 3-test combination, screening NCI was defined as meeting one of the following three criteria: (1) three tests with T-score,40; (2) one test with T-score,40 and one test with T-score,35; or (3) one test with T-score,30. For each 4-test combination, screening NCI was defined as meeting one of the following five criteria: (1) four tests with T-score,40; (2) two tests with T-score,40 and one test with T-score,35; (3) two tests with T-score,35; (4) one test with T-score,40 and one test with T-score,30; or (5) one test with T-score,25. The rationale for this scoring structure was that these combinations would always generate a screening GDS equivalent to 1.0, and is similar to a previously published technique [10]. This screening level for impairment is double that required for impairment with our comprehensive battery (i.e., GDS = 0.05). A more substantial level of impairment is required for the screening tests in order to provide a conservative approach to identifying persons who might be at risk for neurocognitive impairment with a larger overall battery. Sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and odds ratios (OR) were calculated separately for each screening test combination using the global NP PLOS ONE 3 November 2012 Volume 7 Issue 11 e47310
4 impairment from the comprehensive battery as the gold standard. The testing combinations were then ranked by the sum of their sensitivity and specificity. To assure that the classification accuracy estimates were not sensitive to sample anomalies, the data were randomly re-sampled 10,000 times, with replacement (bootstrapped). The bias-corrected and accelerated (BCa) interval method [23] was used to produce 95% confidence intervals around the estimates for sensitivity, specificity, NPV, and PPV. The listings of possible combinations of test from independent domains were generated using perl scripts; statistical analyses were conducted using SAS software [24]. Results Our HIV-infected cohort was predominantly male (95.5%), relatively young (median age 36.4 years, interquartile range (IQR) ), racially and ethnically diverse (48.5% White, 29% Black, 14.0% Hispanic, and 8.5% other race/ethnicity), well educated (34% with post-secondary degree), had few comorbidities (only seven reported current illicit drug use and three had hepatitis C), and healthy (median CD4 count: 546 cells/mm3, IQR ) with 64% receiving ART. The median duration of HIV infection was 5 years (IQR 2 11 years). Prevalence of global NP impairment was low (19%). Rather than decide the optimal combination of tests to define one specific screening battery, we have chosen to present an enumeration of the top-ranked combinations; this provides users with the information needed to select the highest-ranked combination from among those that satisfy site constraints in time, training, cost, or equipment (Table 1). Tables 2, 3, and 4 provide the test combinations that are the ten highest-ranked for 2, 3, and 4-test combinations, respectively. The 2-test screening combination with the best sensitivity and specificity for global NP impairment included the Stroop Color Test and the Hopkins Verbal Learning Test-Revised Learning Trials (11 minutes; sensitivity = 73%; specificity = 83%; Table 2). Interestingly, all of the ten best 2-test combinations included the Stroop Color Test (measuring processing speed), the PASAT (measuring working memory), or the Hopkins Verbal Learning Test-Revised Learning Trials (measuring learning), and the highest-ranked 3-test combination included exactly these three measures (16 minutes; sensitivity = 86%; specificity = 75%; Table 3). The optimal 4-test screening battery added the Action Fluency test to the same tests found in the best 3-test combination and improved specificity but not sensitivity (18 minutes; sensitivity = 86%; specificity = 87%; Table 4). All of the ten best 3-test combinations showed better summed sensitivity and specificity than the best 2-test combination. Some 3-test combinations required comparable or even less administration time and showed equivalent sensitivity plus specificity as the best 2-test combination (Tables 2 3). For example, a screening combination consisting of the Trail Making Test Part A, PASAT and Grooved Pegboard (Non-dominant hand) takes a total of 9 minutes to administer and had slightly higher sensitivity (76%) plus specificity than the best 2-test combination which takes 11 minutes to administer. Several other combinations of very brief screening (,10 min) combinations yielded good sensitivity and specificity as well (Table 5). In examining our results with an eye toward practicality, we considered combinations of measures that would not require specialized equipment (e.g., the PASAT 50 requires an audio player, Grooved Pegboard Test requires a pegboard). The most sensitive and specific combination of tests that could be administered with limited testing stimuli (i.e., examiner, paper testing stimuli, and pencil) was Action Fluency, Stroop Color Test, Trail Making Test B, and the Hopkins Verbal Learning Test- Revised Learning Trials (18 minutes; sensitivity = 70.3%; specificity = 89.4%). Although all neuropsychological tests require a trained examiner for reliable administration, any of the top combinations of tests require relatively minimal training to administer (e.g., mostly the reading of directions and the recording of responses by the examiner); an examiner could be trained to administer and score any particular combination of measures in a limited amount of time (i.e., less than 2 hours of training). In order to further validate the reported test combinations, we also analyzed and compared a previously published combination of tests that has been used in individuals with HIV [25] in our cohort. This 3-test combination, which included Trail Making Test A and B and Digit Symbol, showed poor sensitivity (36.8%) but good specificity (92.5%) in our study cohort of mildly impaired HIV individuals. Discussion Our study reveals that several combinations of traditional neuropsychological tests that require relatively little administration time (i.e.,,20 minutes, and in some cases,10 minutes) can yield good sensitivity and specificity in identifying neurocognitive impairment as assessed by a larger test battery in a relatively high functioning sample of HIV-infected military beneficiaries. There is a great need to identify a sensitive and specific brief cognitive screening battery for detection of mild HIV-related neurocognitive impairment [26]. This is especially true given that cognition impacts medication adherence, employment and quality of life measures [20,27 29]. Additionally, among service members, detection of neurocognitive impairment has critical occupational implications [27]. Tests that tended to be the most sensitive were in the domains of verbal learning, attention/working memory, and processing speed, which is generally consistent with the domains found to be impaired in larger studies of neurocognitive impairment in HIV [30]. These most sensitive and specific domains have been shown to be associated with the frontostriatal neural systems which are commonly disturbed among persons with HIV-infection (for a review see [31]). Our approach, one that examined all possible test combinations across various neurocognitive domains, was empirically driven and unbiased by expectations of what combination of tests would likely be most sensitive and specific. We presented a menu of options, rather than advocate for a specific battery. While this may lead to inconsistent approaches across settings, we believed it was important to not mandate a one size fits all approach. If brevity is most important, the preferred choice appears to be Trail Making Part A, PASAT and the Grooved Pegboard non-dominant hand (9 minutes; 76% sensitivity). While special equipment is required for this battery, only the Grooved Pegboard ($110 at the time of submission of this manuscript) and a device to play an audio file (e.g., computer, CD player, or even a Smartphone) have an associated cost. The PASAT sound file and the Trail Making Part A are in the public domain. Thus, for a small initial investment and less than 10 minutes of administration time, one could screen for neurocognitive impairment utilizing reliable, well-validated measures. The screener with the best combination of sensitivity and specificity (i.e., Action Fluency, Stroop Color, PASAT, and HVLT-R Learning Trials) requires 7 more minutes of assessment time, but is also easy to administer. The two-minute investment to administer Action Fluency appears worthwhile for improved specificity with this battery (i.e., 87.1% versus 75.5%) as compared to the 3-test combination that does not include Action Fluency. PLOS ONE 4 November 2012 Volume 7 Issue 11 e47310
5 Table 2. Top 10 2-test combinations, ranked according to sum of sensitivity and specificity compared to a 120 minute global neuropsychological battery. Rank Tests Administration Time (min) Sensitivity (95% Specificity (95% CI) 1 CI) 1 PPV (95% CI) 1 NPV (95% CI) 1 OR (95% CI) 1 STRPCOL/HVLTR-LRN ( ) 83.1 ( ) 50.0 ( ) 93.0 ( ) 13.3 ( ) 2 HVLTR-LRN/PD ( ) 82.0 ( ) 49.1 ( ) 93.0 ( ) 12.7 ( ) 3 PASAT/BVMTR-LRN ( ) 89.7 ( ) 60.0 ( ) 90.9 ( ) 15.0 ( ) 4 PASAT/HVLTR-LRN ( ) 77.6 ( ) 44.4 ( ) 92.4 ( ) 9.7 ( ) 5 PASAT/PND ( ) 79.5 ( ) 45.8 ( ) 91.9 ( ) 9.5 ( ) 6 HVLTR-LRN/PND ( ) 77.6 ( ) 42.9 ( ) 91.9 ( ) 8.5 ( ) 7 STRPCOL/BVMTR-LRN ( ) 94.4 ( ) 69.0 ( ) 89.9 ( ) 19.7 ( ) 8 STRPCOL/PD ( ) 90.6 ( ) 58.3 ( ) 90.1 ( ) 12.7 ( ) 9 STRPINC/HVLTR-LRN ( ) 82.5 ( ) 46.2 ( ) 91.0 ( ) 8.7 ( ) 10 PASAT/WCST ( ) 86.9 ( ) 51.2 ( ) 90.5 ( ) 10.0 ( ) 1 95% bootstrap CI for Sensitivity, Specificity, PPV and NPV. Abbreviations: BVMTR-LRN, Brief Visuospatial Memory Test-Revised (Learning Trials); CI, Confidence Interval; HVLTR-LRN, Hopkins Verbal Learning Test-Revised (Learning Trials); NPV, Negative Predictive Value; OR, Odds Ratio; PASAT, Paced Auditory Serial Addition Test; PD, Grooved Pegboard-Dominant hand; PND, Grooved Pegboard-non Dominant hand; PPV, Positive Predictive Value; STRPCOL, Stroop Color Test; STRPINC, Stroop Incongruent Test; WCST, Wisconsin Card Sorting Test (Total Errors). doi: /journal.pone t002 The second ranked 3-test combination of Trail Making Test Part A, PASAT, and HVLT-R Learning avoids the requirement of having the color stimuli of the Stroop tests and replaces it with the Trail Making Test, which is widely available and in the public domain. If sensitivity were the most important criteria (which is likely given the desire to identify those who are abnormal), this battery, as well as the top ranked 3-test battery, would seem to be reasonable choices. The menu of options is also important for multiple testing sessions over time. We know that a subset of HIV-infected persons can have fluctuations in cognitive ability over time and that neuropsychological tests are susceptible to practice effects [32]. One could consider switching to non-overlapping screening batteries at different assessment time points to avoid practice effect problems; however, this would require those who administer the tests to be trained on a wider range of instruments and for all assessment instruments to be available, which may not be feasible in some settings. In addition, multiple alternative forms are available for the HVLT-R (and BVMT-R), which is advantageous for eliminating practice effects on those tests that may be most susceptible to these problems (e.g., tests of learning/memory). There are several advantages of using traditional neuropsychological tests as screening batteries as opposed to newly developed screening instruments. Specifically, all of the measures reported in this study have excellent normative data that allow for corrections for demographic factors that can influence neurocognitive test performance such as age, education, sex and ethnicity. All of the measures have been previously validated on large samples with Table 3. Top 10 3-test combinations, ranked according to sum of sensitivity and specificity compared to a 120 minute global neuropsychological battery. Rank Tests Admin. Time (min) Sensitivity Specificity (95% CI) 1 (95% CI) 1 PPV (95% CI) 1 NPV (95% CI) 1 OR (95% CI) 1 STRPCOL/PASAT/HVLTR-LRN ( ) 75.5 ( ) 45.7 ( ) 95.9 ( ) 19.7 ( ) 2 TMTA/PASAT/HVLTR-LRN ( ) 76.3 ( ) 46.4 ( ) 95.2 ( ) 17.2 ( ) 3 SYMS/PASAT/HVLTR-LRN ( ) 79.5 ( ) 48.4 ( ) 93.9 ( ) 14.5 ( ) 4 ACTF/STRPCOL/HVLTR-LRN ( ) 80.0 ( ) 47.5 ( ) 94.1 ( ) 14.5 ( ) 5 PASAT/BVMTR-LRN/PND ( ) 82.1 ( ) 50.9 ( ) 93.4 ( ) 14.7 ( ) 6 PASAT/HVLTR-LRN/PD ( ) 75.6 ( ) 44.9 ( ) 94.4 ( ) 13.8 ( ) 7 STRPCOL/HVLTR-LRN/PD ( ) 78.8 ( ) 46.0 ( ) 94.0 ( ) 13.4 ( ) 8 TMTA/PASAT/PND ( ) 80.1 ( ) 48.3 ( ) 93.3 ( ) 13.0 ( ) 9 ANIMF/STRPCOL/HVLTR-LRN ( ) 80.6 ( ) 47.5 ( ) 93.5 ( ) 12.9 ( ) 10 FAS/STRPCOL/BVMTR-LRN ( ) 91.3 ( ) 63.2 ( ) 91.8 ( ) 19.3 ( ) 1 95% bootstrap CI for Sensitivity, Specificity, PPV and NPV. Abbreviations: ACTF, Action Fluency; ANIMF, Animal Fluency; BVMTR-LRN, Brief Visuospatial Memory Test-Revised (Learning Trials); CI, Confidence Interval; FAS; Letter Fluency; HVLTR-LRN, Hopkins Verbal Learning Test-Revised (Learning Trials); NPV, Negative Predictive Value; OR, Odds Ratio; PASAT, Paced Auditory Serial Addition Test; PD, Grooved Pegboard-Dominant hand; PND, Grooved Pegboard -non Dominant hand; PPV, Positive Predictive Value; STRPCOL, Stroop Color Test; SYMS, WAIS-III Symbol Search; TMTA, Trail Making Test-A. doi: /journal.pone t003 PLOS ONE 5 November 2012 Volume 7 Issue 11 e47310
6 Table 4. Top 10 4-test combinations, ranked according to sum of sensitivity and specificity compared to a 120 minute global neuropsychological battery. Rank Tests Admin. Time (min) Sensitivity Specificity (95% CI) 1 (95% CI) 1 PPV (95% CI) 1 NPV (95% CI) 1 OR (95% CI) 1 ACTF/STRPCOL/PASAT/HVLTR-LRN ( ) 87.1 ( ) 61.5 ( ) 96.4 ( ) 43.2 ( ) 2 STRPCOL/PASAT/HVLTR-LRN/PND ( ) 83.2 ( ) 54.4 ( ) 95.6 ( ) 25.6 ( ) 3 STRPCOL/PASAT/HVLTR-LRN/PD ( ) 85.2 ( ) 56.6 ( ) 95.0 ( ) 24.6 ( ) 4 ACTF/STRPCOL/PASAT/BVMTR-LRN ( ) 92.9 ( ) 71.1 ( ) 93.5 ( ) 35.3 ( ) 5 ACTF/TMTA/PASAT/HVLTR-LRN ( ) 84.0 ( ) 55.4 ( ) 94.9 ( ) 23.2 ( ) 6 ANIMF/STRPCOL/PASAT/HVLTR-LRN ( ) 86.5 ( ) 58.0 ( ) 94.4 ( ) 23.1 ( ) 7 FAS/STRPCOL/PASAT/PND ( ) 88.4 ( ) 60.9 ( ) 93.8 ( ) 23.7 ( ) 8 ACTF/STRPCOL/PASAT/PND ( ) 87.7 ( ) 59.6 ( ) 93.8 ( ) 22.3 ( ) 9 ACTF/SYMS/PASAT/HVLTR-LRN ( ) 88.5 ( ) 60.9 ( ) 93.2 ( ) 21.5 ( ) 10 ACTF/DSYM/PASAT/HVLTR-LRN ( ) 88.2 ( ) 60.9 ( ) 93.1 ( ) 21.0 ( ) 1 95% bootstrap CI for Sensitivity, Specificity, PPV and NPV. Abbreviations: ACTF, Action Fluency; ANIMF, Animal Fluency; BVMTR-LRN, Brief Visuospatial Memory Test-Revised (Learning Trials); CI, Confidence Interval; DSYM, WAIS-III Digit Symbol; FAS, Letter Fluency; HVLTR-LRN, Hopkins Verbal Learning Test-Revised (Learning Trials); NPV, Negative Predictive Value; OR, Odds Ratio; PASAT, Paced Auditory Serial Addition Test; PD, Grooved Pegboard-Dominant hand; PND, Grooved Pegboard -non Dominant hand; PPV, Positive Predictive Value; STRPCOL, Stroop Color Test; SYMS, WAIS-III Symbol Search; TMTA, Trail Making Test-A. doi: /journal.pone t004 excellent reliability and validity. Moreover, most of these tests are very easy to administer and interpret. On the other hand, there are some disadvantages of using these tests. Some measures are copyrighted and have an associated cost as compared to a public domain screening instrument such as the Montreal Cognitive Assessment (MoCA) [33]. Also, in order to capitalize on the normative data, the raw scores would have to be converted into demographically corrected scores using a table look-up or a computerized program and there is an investment for these materials. One can argue, however, that utilizing a screener that does not account for certain demographic factors (in particular age, education, ethnicity) is inappropriate when these variables are known to affect cognitive functioning [20]. For a screening instrument, it may be best to avoid using tests that require some expertise in scoring (e.g., visual learning/memory tests) [34], and in this study other combinations of tests were more sensitive and specific. For neuroaids research, there may be an advantage of the HIV field moving toward a consistent NP battery and standardized approaches to summarizing neurocognitive data. For example, some consensus approaches such as the MATRICS battery in schizophrenia have improved consistency across studies in that research arena ( One possible option for consistency moving forward may be the utilization of the NIH Tool Box ( As of this writing, the specific battery of tests is not available, but the subdomains have been identified and beta testing of the battery is well underway. Studies will be needed to compare traditional neuropsychological assessment measures with those in the NIH Tool Box. With this said, in clinical settings, flexibility and brevity, Table 5. Top 10 testing combinations, ranked according to sum of sensitivity and specificity compared to a 120 minute global neuropsychological battery, that take 10 minutes or less to administer. Rank Tests Admin. Time (min) Sensitivity Specificity (95% (95% CI) 1 CI) 1 PPV (95% CI) 1 NPV (95% CI) 1 OR (95% CI) 1 TMTA/PASAT/PND ( ) 80.1 ( ) 48.3 ( ) 93.3 ( ) 13.0 ( ) 2 ACTF/STRPCOL/PD/PND ( ) 88.1 ( ) 57.8 ( ) 92.8 ( ) 17.5 ( ) 3 STRPCOL/PASAT/PND ( ) 78.1 ( ) 45.2 ( ) 93.1 ( ) 11.1 ( ) 4 ACTF/STRPCOL/DSYM/PD ( ) 94.3 ( ) 71.0 ( ) 90.8 ( ) 24.1 ( ) 5 ACTF/STRPCOL/TMTA/PND ( ) 91.3 ( ) 62.2 ( ) 91.3 ( ) 17.1 ( ) 6 STRPCOL/STRPINC/PASAT/PND ( ) 85.8 ( ) 53.2 ( ) 91.7 ( ) 12.6 ( ) 7 STRPCOL/TMTA/PASAT/PND ( ) 85.8 ( ) 53.2 ( ) 91.7 ( ) 12.6 ( ) 8 ACTF/PASAT/PND ( ) 76.9 ( ) 44.6 ( ) 93.0 ( ) 10.7 ( ) 9 ACTF/STRPCOL/PND ( ) 82.5 ( ) 48.1 ( ) 92.3 ( ) 11.1 ( ) 10 STRPINC/TMTA/PASAT/PND ( ) 85.2 ( ) 52.1 ( ) 91.7 ( ) 12.0 ( ) 1 95% bootstrap CI for Sensitivity, Specificity, PPV and NPV. Abbreviations: ACTF, Action Fluency; CI, Confidence Interval; FAS, Letter Fluency; NPV, Negative Predictive Value; OR, Odds Ratio; PASAT, Paced Auditory Serial Addition Test; PD, Grooved Pegboard-Dominant hand; PND, Grooved Pegboard -non Dominant hand; PPV, Positive Predictive Value; STRPCOL, Stroop Color Test; STROOPINC, Stroop Incongruent Test; TMTA, Trail Making Test-A. doi: /journal.pone t005 PLOS ONE 6 November 2012 Volume 7 Issue 11 e47310
7 with good sensitivity and specificity to larger neuropsychological assessment batteries are paramount; thus, the suggested screening combinations presented herein may have particular utility. The present study is not without limitations. First, our overall impairment rate was very low when utilizing the comprehensive NP battery (19%); therefore, it is difficult to choose a subset of tests to screen for impairment when impairment is relatively limited. The present screening battery may be most appropriate for welltreated HIV populations with few comorbidities, and ideally, participants identified with impairment would be referred for additional more detailed neurocogntive assessment. Another limitation is the choice to include the same NP measures in both the screening battery and the comprehensive NP battery. We believed that eliminating these measures and recalculating a score from the larger battery without these measures would lead to less stable characterization of the cohort across combination examinations. In order to further address the lack of a gold standard in the current study, however, we calculated and compared a previously published 3-test combination (i.e., Trail Making Test A and B and Digit Symbol) [25] within our study cohort. We found that this established 3-test battery was not as sensitive (i.e., 36.8%) as other test combinations that were identified with our methods, which renders further support for the combinations identified in our study. Due to these limitations, our screening batteries need validation among other HIV-infected populations. Lastly, although our screening batteries may show good sensitivity in detecting neurocognitive impairment, it is important to note that the batteries are not necessarily diagnostic of HIV-associated neurocognitive impairment since other potential causes of neurocognitive impairment must be ruled out before the neurocognitive impairment can be deemed to be due to HIV. Moreover, our screening batteries are not meant to diagnose HIVassociated neurocognitive disorders (HAND) given that a HAND diagnosis additionally requires a determination of daily functioning ability [32]. In summary, combinations of widely accepted neuropsychological tests with short implementation times demonstrated adequate sensitivity and specificity compared to a more time intensive NP test battery. Tests of verbal learning, attention/working memory, and processing speed appeared to be particularly useful in detecting NCI. While several screening instruments have been References 1. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, et al. (2010) HIVassociated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: Butters N, Grant I, Haxby J, Judd LL, Martin A, et al. (1990) Assessment of AIDS-related cognitive changes: recommendations of the NIMH Workshop on Neuropsychological Assessment Approaches. J Clin Exp Neuropsychol 12: Malloy PF, Cummings JL, Coffey CE, Duffy J, Fink M, et al. (1997) Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 9: Mattis S (1988) Dementia Rating Scale: Odessa, FL. 5. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, et al. (2002) Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59: Moore DJ, Masliah E, Rippeth JD, Gonzalez R, Carey C, et al. (2006) Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS 20: Reger M, Welsh R, Razani J, Martin DJ, Boone KB (2002) A meta-analysis of the neuropsychological sequelae of HIV infection. J Int Neuropsychol Soc 8: Power C, Selnes OA, Grim JA, McArthur JC (1995) HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 8: McArthur JC, Brew BJ (2010) HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS 24: developed for the detection of HIV-associated NCI, utilizing a combination of validated, relatively easy to administer, neuropsychological tests with established normative data may represent an excellent approach to detecting NCI. Acknowledgments The HIV Neurobehavioral Research Center (HNRC) is supported by Center award MH from NIMH. The San Diego HIV Neurobehavioral Research Center [HNRC] group is affiliated with the University of California, San Diego, the Naval Hospital, San Diego, and the Veterans Affairs San Diego Healthcare System, and includes: Director: Robert Heaton, Ph.D.; Co-Directors: J. Hampton Atkinson, M.D., Ronald J. Ellis, M.D., Ph.D., and J. Allen McCutchan, M.D.; Center Manager: Thomas D. Marcotte, Ph.D.; Jennifer Marquie-Beck, M.P.H.; Melanie Sherman; Neuromedical Component: Ronald J. Ellis, M.D., Ph.D. (P.I.), J. Allen McCutchan, M.D., Scott Letendre, M.D., Edmund Capparelli, Pharm.D., Rachel Schrier, Ph.D., Terry Alexander, R.N., Debra Rosario, M.P.H., Shannon LeBlanc; Neurobehavioral Component: Robert K. Heaton, Ph.D. (P.I.), Steven Paul Woods, Psy.D., Mariana Cherner, Ph.D., David J. Moore, Ph.D., Matthew Dawson; Neuroimaging Component: Terry Jernigan, Ph.D. (P.I.), Christine Fennema-Notestine, Ph.D., Sarah L. Archibald, M.A., John Hesselink, M.D., Jacopo Annese, Ph.D., Michael J. Taylor, Ph.D.; Neurobiology Component: Eliezer Masliah, M.D. (P.I.), Cristian Achim, M.D., Ph.D., Ian Everall, FRCPsych., FRCPath., Ph.D. (Consultant); Neurovirology Component: Douglas Richman, M.D., (P.I.), David M. Smith, M.D.; International Component: J. Allen McCutchan, M.D., (P.I.); Developmental Component: Cristian Achim, M.D., Ph.D.; (P.I.), Stuart Lipton, M.D., Ph.D.; Participant Accrual and Retention Unit: J. Hampton Atkinson, M.D. (P.I.), Rodney von Jaeger, M.P.H.; Data Management Unit: Anthony C. Gamst, Ph.D. (P.I.), Clint Cushman (Data Systems Manager); Statistics Unit: Ian Abramson, Ph.D. (P.I.), Florin Vaida, Ph.D., Reena Deutsch, Ph.D., Anya Umlauf, M.S., Tanya Wolfson, M.A. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, nor the United States Government. Author Contributions Conceived and designed the experiments: DJM. Performed the experiments: BH AW AG NFC. Analyzed the data: MPR LEE. Contributed reagents/materials/analysis tools: MPR LEE. Wrote the paper: DJM MPR LEE KB BH AW AG BKA SLL NFC. 10. Carey CL, Woods SP, Rippeth JD, Gonzalez R, Moore DJ, et al. (2004) Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol 18: Smith CA, van Gorp WG, Ryan ER, Ferrando SJ, Rabkin J (2003) Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV dementia scale. J Acquir Immune Defic Syndr 33: Richardson MA, Morgan EE, Vielhauer MJ, Cuevas CA, Buondonno LM, et al. (2005) Utility of the HIV dementia scale in assessing risk for significant HIVrelated cognitive-motor deficits in a high-risk urban adult sample. AIDS Care 17: Morgan EE, Woods SP, Scott JC, Childers M, Marquie-Beck J, et al. (2008) Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol 30: Jones BN, Teng EL, Folstein MF, Harrison KS (1993) A new bedside test of cognition for patients with HIV infection. Ann Intern Med 119: Berghuis JP, Uldall KK, Lalonde B (1999) Validity of two scales in identifying HIV-associated dementia. J Acquir Immune Defic Syndr 21: Cysique LA, Maruff P, Brew BJ (2004) Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 61: Sacktor NC, Wong M, Nakasujja N, Skolasky R, Selnes O, et al. (2005) The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 19: Marconi VC, Grandits GA, Weintrob AC, Chun H, Landrum ML, et al. (2010) Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther 7: 14. PLOS ONE 7 November 2012 Volume 7 Issue 11 e47310
8 19. Cherner M, Suarez P, Lazzaretto D, Fortuny LA, Mindt MR, et al. (2007) Demographically corrected norms for the Brief Visuospatial Memory Testrevised and Hopkins Verbal Learning Test-revised in monolingual Spanish speakers from the U.S.-Mexico border region. Arch Clin Neuropsychol 22: Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, et al. (2004) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10: Norman MA, Moore DJ, Taylor M, Franklin D Jr, Cysique L, et al. (2011) Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test- Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64- Card Version. J Clin Exp Neuropsychol 33: Woods SP, Scott JC, Fields JA, Poquette A, Troster AI (2008) Executive dysfunction and neuropsychiatric symptoms predict lower health status in essential tremor. Cogn Behav Neurol 21: Efron BT (1998) An Introduction to the Bootstrap. Boca Raton: Chapman and Hall. 24. SAS [computer program]. Version 9.1. Cary, N.C. 25. Ellis RJ, Evans SR, Clifford DB, Moo LR, McArthur JC, et al. (2005) Clinical validation of the NeuroScreen. J of Neurovirol 11: Valcour VG (2011) Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools. Top Antivir Med 19: Gorman AA, Foley JM, Ettenhofer ML, Hinkin CH, van Gorp WG (2009) Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev 19: Ettenhofer ML, Foley J, Castellon SA, Hinkin CH (2010) Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology 74: Parsons TD, Braaten AJ, Hall CD, Robertson KR (2006) Better quality of life with neuropsychological improvement on HAART. Health Qual Life Outcomes 4: Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17: Woods SP, Moore DJ, Weber E, Grant I (2009) Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 19: Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, et al. (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, et al. (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53: Achenbach TM, Edelbrock C, Howell CT (1987) Empirically based assessment of the behavioral/emotional problems of 2- and 3- year-old children. J Abnorm Child Psychol 15: PLOS ONE 8 November 2012 Volume 7 Issue 11 e47310
Detecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors?
Detecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors? Jennifer Lewis, PsyD; Mathew Hirsch, PsyD & Susan Abramowitz, PhD NYU School of Medicine, New York, NY Friday,
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationInternational Symposium on. Barcelona, May 5 th and 6 th 2011
th International Symposium on Barcelona, May 5 th and 6 th 2011 4rd Symposium on Psychiatry and HIV --- Barcelona, May 6th 2010 Neurocognitive Testing in HIV Infection: How to Implement this Assessment
More informationLow prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons
Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons Nancy F. Crum-Cianflone, David J. Moore, Scott Letendre, et al. Neurology 2013;80;371; Published online before
More informationThe Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV
The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV Arianna Perra, P syd, Moira Dux, PhD Terry Lee- Wilk, PhD HIV and HCV in the VA VA is the largest provider
More informationIssues of Neuropsychological Assessment in International Settings
Issues of Neuropsychological Assessment in International Settings Kevin Robertson, Ph.D. Director of Neuropsychology, Neurology University of North Carolina at Chapel Hill Igor Grant, M.D. Director, HIV
More informationDynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy
Published Ahead of Print on May 27, 2009 as 10.1212/WNL.0b013e3181ab2b3b Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy L.A. Cysique, PhD F. Vaida, PhD
More informationInternational Forum on HIV and Rehabilitation Research
Neurocognitive screening and behavioural interventions for HIV-Associated Neurocognitive Disorders (HAND) International Forum on HIV and Rehabilitation Research Translating Research Evidence from the Canada-UK
More informationHIV & Women: Neurological Issues
HIV & Women: Neurological Issues Scott Letendre, M.D. Professor of Medicine University of California, San Diego 1 Do women differ from men in their risk for neurocognitive and mood disorders? 2 As the
More informationThe prevalence of HIV-associated neurocognitive
The authors investigated the combined age and HIV effects on cognitive functions in 146 individuals, 116 of whom had HIV infection. Fortytwo percent had HIV-associated neurocognitive disorder, and all
More informationHAND is Common and Important in Patients on ART
HAND is Common and Important in Patients on ART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego How is HAND diagnosed? How prevalent is it? Points
More informationMetabolic Syndrome is Associated with Neurocognitive Deficits in Persons Living with HIV
Metabolic Syndrome is Associated with Neurocognitive Deficits in Persons Living with HIV Jessica L. Montoya, Ph.D. Postdoctoral Fellow Department of Psychiatry, UC San Diego 9 th International Workshop
More informationApproach to HIV Associated Neurocognitive disorders (HAND)
Approach to HIV Associated Neurocognitive disorders (HAND) Dinesh Singh MB ChB (Natal), M Med (Psych) (Natal), F CPsych (SA), MS (epi) (Columbia, USA), PhD (candidate UKZN) 2 October 2009 ICC, Durban Overview
More informationHow to Implement this Assessment in the Clinical Prac5ce?
5th Interna*onal Symposium on Neuropsychiatry HIV - - - Barcelona, May 24-25th, 2012 Neuropsychological Screening in HIV Infec6on: How to Implement this Assessment in the Clinical Prac5ce? Jose A. Muñoz-
More informationHIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project
DOI: 10.1111/hiv.12137 ORIGINAL RESEARCH HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project NS Ku, 1 Y Lee, 2 JY Ahn, 1 JE Song, 1 MH Kim, 1 SB Kim, 1 SJ Jeong,
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationMeasurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History
Measurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History Group Means for NP and MMPI Variables N=381 Consecutive
More informationLambros Messinis PhD. Neuropsychology Section, Department of Neurology, University of Patras Medical School
Lambros Messinis PhD Neuropsychology Section, Department of Neurology, University of Patras Medical School Type 2 Diabetes Mellitus is a modern day epidemic Age is a significant predictor of diabetes Males
More informationSince the introduction of highly-active antiretroviral
Family History of Dementia Predicts Worse Neuropsychological Functioning Among HIV-Infected Persons David J. Moore, Ph.D. Miguel Arce, B.A. Suzanne Moseley, B.S. J. Allen McCutchan, M.D. Jennifer Marquie-Beck,
More informationThe Relationship Between Age and Cognitive Function in HIV-Infected Men
The Relationship Between Age and Cognitive Function in HIV-Infected en Emily C. Kissel Nicole D. Pukay-artin, B.A. Robert A. Bornstein, Ph.D. Several studies have identified increased age as a risk factor
More informationORIGINAL CONTRIBUTION. Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion
ORIGINAL CONTRIBUTION Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion Thomas D. Marcotte, PhD; Reena Deutsch, PhD; J. Allen McCutchan, MD;
More informationThe Role of Cardiovascular Risk and Aging in Memory Performance in a Sample of Veterans with HIV
The Role of Cardiovascular Risk and Aging in Memory Performance in a Sample of Veterans with HIV LYNN KAKOS, PH.D. VA MARYLAND HEALTH CARE SYSTEM (VAMHCS) OBJECTIVES HIV in the VA Neurocognitive profile
More informationDefinitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders
Definitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders Prepared by Igor Grant for Working Group 1 consisting of: Desiree Byrd, Mariana Cherner, David
More informationGood Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection
BRIEF REPORT: CLINICAL SCIENCE Good Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection Gustavo D. Lopardo, MD,* Emiliano Bissio, MD,* María del C. Iannella,*
More informationInflammation Relates to Poorer Complex Motor Performance Among Adults Living With HIV on Suppressive Antiretroviral Therapy
EPIDEMIOLOGY Inflammation Relates to Poorer Complex Motor Performance Among Adults Living With HIV on Suppressive Antiretroviral Therapy Jessica L. Montoya, PhD,* Laura M. Campbell, BS, Emily W. Paolillo,
More informationOriginal Article. J Young Pharm, 2016; 8(3): A multifaceted peer reviewed journal in the field of Pharmacy
J Young Pharm, 2016; 8(3): 279-283 A multifaceted peer reviewed journal in the field of Pharmacy www.jyoungpharm.org www.phcog.net Original Article Impact of HIV associated neurocognitive disorders on
More informationCOGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL
COGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL Principal Investigator Dr. Zaheer Bagha Supervisors Prof. E. Amayo Prof. A. M. Adam Dr. J. O. Mecha INTRODUCTION
More informationNeurocognitive Impairments in HIV: Natural History, Impacts on Everyday Functioning and Promising Interventions
Neurocognitive Impairments in HIV: Natural History, Impacts on Everyday Functioning and Promising Interventions Sean B. Rourke, Ph.D. Scientist and Neuropsychologist, St. Michael s Hospital Director, CIHR
More informationPlenary Session 2 Psychometric Assessment. Ralph H B Benedict, PhD, ABPP-CN Professor of Neurology and Psychiatry SUNY Buffalo
Plenary Session 2 Psychometric Assessment Ralph H B Benedict, PhD, ABPP-CN Professor of Neurology and Psychiatry SUNY Buffalo Reliability Validity Group Discrimination, Sensitivity Validity Association
More informationNEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
More informationHIV-Associated Neurocognitive Disorders (HAND) Aroonsiri Sangarlangkarn, MD, MPH, Jonathan S. Appelbaum, MD, FACP
HIV-Associated Neurocognitive Disorders (HAND) Aroonsiri Sangarlangkarn, MD, MPH, Jonathan S. Appelbaum, MD, FACP Educational Objectives By the end of the session, learners will be able to: 1. Describe
More informationRates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection
Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection Teresa H. Evering a, Allison Applebaum b, Melissa La Mar a,
More informationHIV Associated Neurocognitive Disorders in the era of modern CART
HIV Associated Neurocognitive Disorders in the era of modern CART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego Points to be covered HIV associated
More informationThe Influence of Sleep on Cognition in Breast Cancer
The Influence of Sleep on Cognition in Breast Cancer Sonia Ancoli-Israel, PhD Professor of Psychiatry and Medicine University it of California i San Diego Fatigue by Rodin Supported by NIC CA112035, UL1RR031980
More informationAsymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline Igor Grant, MD Donald R. Franklin, Jr., BS Reena Deutsch, PhD Steven P. Woods, PsyD Florin Vaida, PhD Ronald
More informationCognitive impairment among Indonesia HIV naïve patients
Neurology Asia 2015; 20(2) : 155 160 Cognitive impairment among Indonesia HIV naïve patients 1 Riwanti Estiasari MD, 1 Darma Imran MD, 1 Diatri Nari Lastri MD, 1 Pukovisa Prawirohardjo MD, 1,2 Patricia
More informationForget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?)
Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?) Dr Simon Rackstraw FRCP Medical Director, Mildmay Hospital, London Consultant
More informationCOGNITIVE FUNCTIONING IN ADULTS AGING WITH HIV: EXPLORING COGNITIVE SUBTYPES AND INFLUENTIAL FACTORS PARIYA L. FAZELI
COGNITIVE FUNCTIONING IN ADULTS AGING WITH HIV: EXPLORING COGNITIVE SUBTYPES AND INFLUENTIAL FACTORS by PARIYA L. FAZELI DAVID E. VANCE, COMMITTEE CO-CHAIR KARLENE K. BALL, COMMITTEE CO-CHAIR VIRGINIA
More informationInternational HIV Dementia Scale:
ORIGINAL RESEARCH International HIV Dementia Scale: screening for HIV-associated neurocognitive disorders in occupational settings CH Van Wijk 1,2 and WAJ Meintjes 2 1 Institute for Maritime Medicine,
More informationImprovement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors
(2000) 6, 84 ± 88 ã 2000, Inc. www.jneurovirol.com Short Communication Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors Ned Charlton Sacktor*,1, Richard
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationElderly Norms for the Hopkins Verbal Learning Test-Revised*
The Clinical Neuropsychologist -//-$., Vol., No., pp. - Swets & Zeitlinger Elderly Norms for the Hopkins Verbal Learning Test-Revised* Rodney D. Vanderploeg, John A. Schinka, Tatyana Jones, Brent J. Small,
More informationTHE INFLUENCE OF CULTURE ON NEUROPSYCHOLOGICAL TESTING IN ZAMBIA
THE INFLUENCE OF CULTURE ON NEUROPSYCHOLOGICAL TESTING IN ZAMBIA BY MARIA ANNA AKANI A thesis submitted to the University of Zambia in fulfilment of the requirements for the degree of Masters in Science
More informationCognitive Impairment and Magnetic Resonance Changes in Multiple Sclerosis. Background
Cognitive Impairment and Magnetic Resonance Changes in Multiple Sclerosis Victoria A Levasseur 1,2, Samantha Lancia 1, Gautam Adusumilli 1, Zach Goodman 1, Stuart D. Cook 3, Diego Cadavid 4, Robert T.
More informationEvaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature
Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature Amy R. Zipursky a,b, David Gogolishvili a, Sergio Rueda a,b, Jason Brunetta c, Adriana
More informationNeuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
More informationAPPENDIX A TASK DEVELOPMENT AND NORMATIVE DATA
APPENDIX A TASK DEVELOPMENT AND NORMATIVE DATA The normative sample included 641 HIV-1 seronegative gay men drawn from the Multicenter AIDS Cohort Study (MACS). Subjects received a test battery consisting
More informationAn Initial Validation of Virtual Human Administered Neuropsychological Assessments
Annual Review of Cybertherapy and Telemedicine 2017 123 An Initial Validation of Virtual Human Administered Neuropsychological Assessments Thomas D. PARSONS a,*, Paul SCHERMERHORN b, Timothy MCMAHAN a,
More informationDr Ria Daly. Birmingham Heartlands Hospital. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Ria Daly Birmingham Heartlands Hospital 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual Conference of the
More informationCRITICALLY APPRAISED PAPER
CRITICALLY APPRAISED PAPER Kesler, S., Hadi Hosseini, S. M., Heckler, C., Janelsins, M., Palesh, O., Mustian, K., & Morrow, G. (2013). Cognitive training for improving executive function in chemotherapy-treated
More informationPPMI Cognitive-Behavioral Working Group. Daniel Weintraub, MD
PPMI Cognitive-Behavioral Working Group Daniel Weintraub, MD PPMI Annual Meeting - May 6-7, 2014 Membership Daniel Weintraub WG Chair Tanya Simuni Steering Committee Shirley Lasch IND Chris Coffey, Chelsea
More informationNational HIV Nurses Association (NHIVNA) Study Day in collaboration with the British Psychological Society Current Issues in HIV
National HIV Nurses Association (NHIVNA) Study Day in collaboration with the British Psychological Society Current Issues in HIV Dr Matthew Jones-Chesters University of East London 17 October 2012, Hilton
More informationScott Letendre, M.D. Curriculum Vitae March 1, 2008
Scott Letendre, M.D. Curriculum Vitae March 1, 2008 P ERSONAL I NFORMATION Present Position Associate Professor of Medicine University of California, San Diego Office HIV Neurobehavioral Research Center
More informationBase Rates of Impaired Neuropsychological Test Performance Among Healthy Older Adults
Archives of Clinical Neuropsychology, Vol. 13, No. 6, pp. 503 511, 1998 Copyright 1998 National Academy of Neuropsychology Printed in the USA. All rights reserved 0887-6177/98 $19.00.00 PII S0887-6177(97)00037-1
More informationEngagement is Key to Effectiveness of Individualized Texting for Adherence Building (itab) Among HIV+ Methamphetamine Users
Engagement is Key to Effectiveness of Individualized Texting for Adherence Building (itab) Among HIV+ Methamphetamine Users J.L. Montoya, A.S. Rooney, B. Gouaux, A. Umlauf, C. Sanders, C.A. Depp, J.H.
More informationThe Impact of HIV-Associated Neuropsychological Impairment on Everyday Functioning
Fordham University DigitalResearch@Fordham Psychology Faculty Publications Psychology 2004 The Impact of HIV-Associated Neuropsychological Impairment on Everyday Functioning Robert K. Heaton University
More informationCALIFORNIA STATE UNIVERSITY, NORTHRIDGE APATHY AND DEPRESSION AS PREDICTORS OF NEUROCOGNITVE
CALIFORNIA STATE UNIVERSITY, NORTHRIDGE APATHY AND DEPRESSION AS PREDICTORS OF NEUROCOGNITVE PERFORMANCE AND PSYCHOSOCIAL FUNCTIONING IN AN HIV-POSITIVE POPULATION A thesis submitted in partial fulfillment
More informationProcess of a neuropsychological assessment
Test selection Process of a neuropsychological assessment Gather information Review of information provided by referrer and if possible review of medical records Interview with client and his/her relative
More informationDifferential diagnosis between depression and neurocognitive impairment in HIV-infected persons
Differential diagnosis between depression and neurocognitive impairment in HIV-infected persons Dr. Adriana Carvalhal, MD, MSc, PhD University of Toronto - Canada Disclosure Research: Canadian Institute
More informationCRITICALLY APPRAISED PAPER (CAP)
CRITICALLY APPRAISED PAPER (CAP) Godefroy, O., Fickl, A., Roussel, M., Auribault, C., Bugnicourt, J. M., Lamy, C., Petitnicolas, G. (2011). Is the Montreal cognitive assessment superior to the mini-mental
More informationClinical Study Depressive Symptom Clusters and Neuropsychological Performance in Mild Alzheimer s and Cognitively Normal Elderly
Hindawi Publishing Corporation Depression Research and Treatment Volume 2011, Article ID 396958, 6 pages doi:10.1155/2011/396958 Clinical Study Depressive Symptom Clusters and Neuropsychological Performance
More informationClient/Testing Information
Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults Developed By Robert K. Heaton, PhD, S. Walden
More informationCharacterizing HIV-Associated Neurocognitive Disorder in Two Underserved Sociodemographic Groups
University of Miami Scholarly Repository Open Access Dissertations Electronic Theses and Dissertations 2015-03-31 Characterizing HIV-Associated Neurocognitive Disorder in Two Underserved Sociodemographic
More informationBaseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston
Article ID: ISSN 2046-1690 Baseline Characteristics of Patients Attending the www.thealzcenter.org Memory Clinic Serving the South Shore of Boston Corresponding Author: Dr. Anil K Nair, Chief of Neurology,
More informationProgress in understanding the pathogenesis of HIV-1-
The authors previously found a strong association between elevated HIV proviral DNA (HIV DNA) and a diagnosis of HIV-1-associated dementia (HAD) vs. normal cognition. It is unclear whether HIV DNA globally
More informationWHI Memory Study (WHIMS) Investigator Data Release Data Preparation Guide April 2014
WHI Memory Study (WHIMS) Investigator Data Release Data Preparation Guide April 2014 1. Introduction This release consists of a single data set from the WHIMS Epidemiology of Cognitive Health Outcomes
More informationActive Methamphetamine Use is Associated with Antrietroviral Medication Nonadherence
Active Methamphetamine Use is Associated with Antrietroviral Medication Nonadherence D.J. Moore, A.S. Rooney, J.L. Montoya, K.B. Casaletto, B. Gouaux, C.A. Depp, J. H. Atkinson, and the HNRP group June
More informationEffects of Comorbid Disease on Pre-treatment Neurobehavioral Functioning. Sunita K. Patel, PhD Assistant Professor. City of Hope Medical Center
Effects of Comorbid Disease on Pre-treatment Neurobehavioral Functioning. Sunita K. Patel, PhD Assistant Professor City of Hope Medical Center Duarte, California. Pre-Chemotherapy e e apycognitive Functioning
More informationCHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
More informationCognition in high-functioning HIV-seropositive males:
: A role for cognitive reserve? M.H.M. Ensing First supervisor: M.J.E. van Zandvoort Second supervisor: A. Keizer Student number: 3518949 Date: 10-06-2016 Abstract Background HIV is a well-known infection,
More informationCognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.
Cognitive Screening in Risk Assessment Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University Outline of Talk Definition of Dementia and MCI Incidence and Prevalence
More informationORIGINAL CONTRIBUTION. Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals
ORIGINAL CONTRIBUTION Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals Sid E. O Bryant, PhD; Joy D. Humphreys, MA; Glenn E. Smith, PhD; Robert J. Ivnik, PhD; Neill
More informationKorean-VCI Harmonization Standardization- Neuropsychology Protocol (K-VCIHS-NP)
Korean-VCI Harmonization Standardization- Neuropsychology Protocol (K-VCIHS-NP) Yeonwook Kang, Ph.D. Department of Psychology, Hallym University Department of Neurology, Hallym University Sacred Heart
More informationNIH Toolbox. Scoring and Interpretation Guide. September 18, 2012
NIH Toolbox Scoring and Interpretation Guide September 18, 2012 Jerry Slotkin, PhD Cindy Nowinski, MD, PhD Ron Hays, PhD Jennifer Beaumont, MS James Griffith, PhD Susan Magasi, PhD John Salsman, PhD Richard
More informationMethamphetamine (MA) is a potent, highly addictive,
Elevated Neurobehavioral Symptoms Are Associated With Everyday Functioning Problems in Chronic Methamphetamine Users Chronic methamphetamine (MA) use is commonly associated with neural injury and neurocognitive
More informationTable 1: Summary of measures of cognitive fatigability operationalised in existing research.
Table 1: Summary of measures of cognitive fatigability operationalised in existing research. Candidate Mmeasures Studies Procedure Self-reported fatigue measure Key Findings The auditory As and auditory
More informationAdaptive Design in CIAS
Adaptive Design in CIAS or If you don t know where you re going, any road will get you there Michael Sand, PhD, MPH Senior Clinical Program Leader, CNS Boehringer Ingelheim Disclosures I m an employee
More informationORIGINAL CONTRIBUTION. Factors Associated With Incident Human Immunodeficiency Virus Dementia
ORIGINAL CONTRIBUTION Factors Associated With Incident Human Immunodeficiency Virus Dementia Yaakov Stern, PhD; Michael P. McDermott, PhD; Steven Albert, PhD; Donna Palumbo, PhD; Ola A. Selnes, PhD; Justin
More informationWhile great progress has been made in understanding
Human immunodeficiency virus (HIV) DNA in peripheral blood mononuclear cells was previously associated with neuropsychological function. By including individuals encompassing the full range of HIV-1-associated
More informationConcurrent validity of WAIS-III short forms in a geriatric sample with suspected dementia: Verbal, performance and full scale IQ scores
Archives of Clinical Neuropsychology 20 (2005) 1043 1051 Concurrent validity of WAIS-III short forms in a geriatric sample with suspected dementia: Verbal, performance and full scale IQ scores Brian L.
More informationUDS version 3 Summary of major changes to UDS form packets
UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options
More informationA Systematic Review of the Screening Accuracy of the HIV Dementia Scale and International HIV Dementia Scale
A Systematic Review of the Screening Accuracy of the HIV Dementia Scale and International HIV Dementia Scale Lewis John Haddow 1 *, Sian Floyd 2, Andrew Copas 1, Richard John Cary Gilson 1 1 Centre for
More informationRapidly-administered short forms of the Wechsler Adult Intelligence Scale 3rd edition
Archives of Clinical Neuropsychology 22 (2007) 917 924 Abstract Rapidly-administered short forms of the Wechsler Adult Intelligence Scale 3rd edition Alison J. Donnell a, Neil Pliskin a, James Holdnack
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationThe exploration of neuropsychological disorders in HAART- naïve young adults in South Africa
1 The exploration of neuropsychological disorders in HAART- naïve young adults in South Africa Nomakhawuta Moshani ACSENT Laboratory Department of Psychology University of Cape Town Supervisors: Dr Kevin
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationThe Impact of HIV and Aging on the Brain Scott Letendre, M.D.
The Impact of HIV and Aging on the Brain Scott Letendre, M.D. Professor of Medicine and Psychiatry University of California, San Diego Disclosures Research funds were paid to UC San Diego on behalf of
More informationHigh rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents
High rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents YasotharanParamesparan, Jane Ashby, Lucy Garvey, Caroline Foster, Sarah Fidler, Alan Winston Background
More informationComputerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment*
DOI: 10.1111/j.1468-1293.2010.00910.x HIV Medicine (2011), 12, 472 480 ORIGINAL RESEARCH r 2011 British HIV Association Computerized testing augments pencil-and-paper tasks in measuring HIV-associated
More informationHIV Dementia Scale and Psychomotor Slowing The Best Methods in Screening for Neuro-AIDS
HIV Dementia Scale and Psychomotor Slowing The Best Methods in Screening for Neuro-AIDS Hans-Jürgen von Giesen, M.D. Bernhard A. Haslinger, M.D. Simone Rohe Hubertus Köller, M.D. Gabriele Arendt, M.D.
More informationAD Prevention Trials: An Industry Perspective
AD Prevention Trials: An Industry Perspective Robert A. Lasser, MD, MBA Global Development Lead, Product Development Group Medical Director, Neurodegenerative Disorders F. Hoffmann - La Roche Ltd Regulatory
More informationImproving the Methodology for Assessing Mild Cognitive Impairment Across the Lifespan
Improving the Methodology for Assessing Mild Cognitive Impairment Across the Lifespan Grant L. Iverson, Ph.D, Professor Department of Physical Medicine and Rehabilitation Harvard Medical School & Red Sox
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationPRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA
PRELIMINARY RYAN WHITE HIV/AIDS PROGRAM CLINICAL CARE CONFERENCE AGENDA 9:00 9:15 AM Welcome and Introductions TUESDAY, DECEMBER 15, 2015 9:00 AM 5:05 PM 9:15 9:45 AM Update on the Ryan White HIV/AIDS
More informationAPPENDIX A. Search Strategy. Medline
Appendix_Zipursky APPENDIX A Search Strategy Medline Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) Search Strategy: --------------------------------------------------------------------------------
More information*Corresponding Author: Steven Paul Woods:
Pill burden influences the association between time-based prospective memory and antiretroviral therapy adherence in younger but not older HIV-infected adults David P. Sheppard, MA Erica Weber, PhD Kaitlin
More informationDemystifying the Neuropsychological Evaluation Report. Clinical Neuropsychologist 17 March 2017 Program Director, Neurobehavioral Program
Demystifying the Neuropsychological Evaluation Report Jennifer R. Cromer, PhD BIAC Annual Conference Clinical Neuropsychologist 17 March 2017 Program Director, Neurobehavioral Program 84% of neuropsychologists
More informationAt the Intersection of Methamphetamine Use, Aging, and HIV Disease
At the Intersection of Methamphetamine Use, Aging, and HIV Disease Steen Paul Woods, Psy.D. Professor of Psychiatry Translational Methamphetamine AIDS Research Center (TMARC) Training in Research on Addictions
More informationUDS Progress Report. -Standardization and Training Meeting 11/18/05, Chicago. -Data Managers Meeting 1/20/06, Chicago
UDS Progress Report -Standardization and Training Meeting 11/18/05, Chicago -Data Managers Meeting 1/20/06, Chicago -Training material available: Gold standard UDS informant and participant interviews
More informationNeuropsychological assessment in HIV/AIDS and its challenges in Galati County
Neuropsychological assessment in HIV/AIDS and its challenges in Galati County Manuela Arbune Dunarea de Jos U i e sit Galati București, October 5-6, 2015 Background HAND persists despite ARV (~50%). Neu
More information